

Poster #	ECP	First Name	Last Name	Organization	Paper Title
1	ECP	Alessia	Angelillo	Department Of Pharmacy, Federico II, Naples	Lipid self-assembling nanoparticles for the development of novel mRNA-based vaccines
2	ECP	Akilandeswari	Balachandran	Astrazeneca	Automated qPCR Platform Accelerates Oligonucleotide Therapeutics Profiling
3		Veronica	Berntsson	AstraZeneca AB	Process and stability considerations for siRNA drug products in early clinical phase
4		Raghu	Bhushan	Eurofins Discoverx	Advancing Obesity Drug Discovery from Bench to Bedside with Qualified Cell-based Assays for GLP-1 & Beyond
5	ECP	Fang-Ching	Chao	Astrazeneca	Quantifying endosomal escape of oligonucleotides
6	ECP	Miriam	Cipullo	Astrazeneca	Deciphering upstream molecular mechanisms of cell death pathways implicated in ASO-mediated liver toxicity
7	ECP	Nathan	Dupertuis	Oryl Photonics	Novel light scattering instrument for aggregation and solubility measurement
8					Poster not assigned
9	ECP	Sarantuya	Enkhjargal	Mongolian national university of medical science	A deep-intronic FKTN variant creates a pseudoexon, causing truncated protein in Fukuyama muscular dystrophy (FCMD). Antisense oligonucleotides (ASOs) targeting the aberrant splice site restored normal mRNA, FKTN protein, and alpha-dystroglycan glycosylation in patient cells. ASO-mediated pseudoexon skipping shows therapeutic potential for this severe FCMD subtype.
10		Anna-Karin	Fransson	Merck Life Science KGaA	MULTI-seq (Lipid-Modified Oligos) - Multiplexing for Single Cell RNAseq
11		Pernilla	Gregersson	Astrazeneca	An in vitro approach to Determine the Duration of Action for GalNAc-Conjugated siRNAs using long-term 3D-cultures of primary human hepatocytes
12		Julia	Grönros	Ribocure Pharmaceuticals AB	Effects of oligonucleotide drug, RBD8088, in mouse models of human glioblastoma
13		Nikos	Hatzakis	University Of Copenhagen	Imaging biology as it happens: unlocking and controlling oligonucleotide cell entry, release and response by 4D imaging and machine learning analysis
14		Tomas	Jankauskas	Neuraldeep.net	3D-Printed Labware Revolution: Sustainable, Precision Tools for Accelerating Therapeutic Oligo Development
15		Linnea	Johansson	Astrazeneca	Spatially resolved transcriptomics of mouse lung for investigative safety of inhaled antisense oligonucleotides
16	ECP	Alexandre	Khuu	Servier	Identification of Proteins Modulating ASO Activity in Glioblastoma
17	ECP	Josefin	Klang	Astrazeneca	Profiling Off-target Safety of Oligonucleotide Therapeutics via Advanced Transcriptomics
18		Christian	Klein	Agilent Technologies	Determination of Identity, Purity, Assay, and Impurity Profile for a Ligand-Conjugated Antisense Oligonucleotide
19		Andrea	Lauri	Axxam	Gymnosis-delivered antisense oligonucleotides and siRNA: screening and validation for target down-regulation in a neurological cell model
20		Charles	Leach	Ncardia	Development of robust iPSC platforms for accurate predictions of efficacy and toxicity of RNA based modalities.
21		Meiling	Li	F.Hoffmann-La Roche	Threose Nucleic Acids (TNA): Novel sugar chemistry with the potential for next generation gapmer designs
22	ECP & Flash poster presenter	Filipa	Louro	AstraZeneca	Engineering Hybrid Extracellular Vesicles for mRNA delivery
23					Poster not assigned
24	ECP	Sagar	Mahale	Gothenburg University	Dissecting coding and noncoding roles of a bifunctional genomic locus reveals a druggable vulnerability in cancer cell division.
25	ECP & Flash poster presenter	Jacopo	Manigrasso	Astrazeneca	Comprehensive Annotation of the Human Coding Transcriptome: A Resource for Designing RNA-Targeting Therapeutics
26		Amy	Mawdesley	Newcells Biotech	Assessing the Safety of Antisense Oligonucleotides (ASOs) Using the aProximate™ Renal Proximal Tubule Model

27		Peiman	Mirfakhraee	Beckman Coulter	Cydem VT Automated Clone Screening System
28					Poster not assigned
29	ECP & Flash poster presenter	Sofia	Nilsson	Ribocure Pharmaceuticals	Combination therapy with GalNAc-siRNA drugs targeting both PCSK9 and APOC3 resulted in enhanced lipid lowering in mice
30		Christina	Nodin	Cellectricon AB	Detection of acute and delayed onset toxicity effects of ASOs using in vitro neuronal models
31	ECP	Ellen	Parkes	University Of Oxford	Magnetic Activation of Spherical Nucleic Acids for the Remote Control of Synthetic Cells
32	ECP	Ioanna	Patsi	Novo Nordisk A/s	siRNA Quantification Techniques: An Investigation of Sensitivity and Efficiency in Two De-tection Methods
33		Soniya	Savant Botla	Astrazeneca	An ex vivo brain slice culture model for screening oligonucleotide therapeutics
34		Christine	Schwenk	InSphero AG	Adeno-associated virus capsid variant screen for diabetes research: building a scalable methodology for modification of gene expression in primary human islets
35	ECP	Evgeniia	Shcherbinina	University Of Gothenburg	Nuclear RNA interference: Harnessing the power of siRNAs for Cancer Therapy
36		Martin	Svensson	Astrazeneca R&d Gothenburg	Next Generation Therapeutics and Aqueous Workflows: Integrating Automation with Emerging Modalities
37	ECP	Louis	Szeponik	AstraZeneca	Tissue imaging of oligonucleotides – cell type specific distribution and knock-down analysis in the same tissue section
38		Juan	Valcarcel	CRG	Splice switching antisense oligonucleotides targeting NUMB display therapeutic affects in four mouse models of lung adenocarcinoma
39	ECP & Flash poster presenter	Daniel	Van Leeuwen	Astrazeneca	Deciphering the impact of toxic antisense oligonucleotide (ASO) gapmer off-target (OT) RNA degradation on OT protein level
40		Prasad	Wakchaure	Astrazeneca	Discovery of Shikimic Acid Templated AZ Proprietary GalNAc for Targeted Delivery of Oligonucleotides to the Liver
41		Takashi	Willebrand	Chempartner	An Integrated Oligonucleotide Synthesis and Cellular In Vitro Assay Platform to Support Oligonucleotide-Based Drug Discovery and Development